(R)-tert-butyl (1-(methoxy(methyl)amino)-1-oxobutan-2-yl)carbamate | 477940-53-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-tert-butyl (1-(methoxy(methyl)amino)-1-oxobutan-2-yl)carbamate
• 英文别名: [(R)-1-(methoxy-methyl-carbamoyl)-propyl]-carbamic acid tert-butyl ester；tert-butyl N-[(2R)-1-[methoxy(methyl)amino]-1-oxobutan-2-yl]carbamate
• CAS: 477940-53-7
• 化学式: C₁₁H₂₂N₂O₄
• 分子量: 246.307
• InChiKey: UETSWVCUPQBUGT-MRVPVSSYSA-N

物化性质

• 密度：
  1.054±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl (1-(methoxy(methyl)amino)-1-oxobutan-2-yl)carbamate 在 lithium aluminium tetrahydride 、 盐酸羟胺 、 三乙胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 27.0h， 生成
  参考文献：
  名称：

  Binding cooperativity between a ligand carbonyl group and a hydrophobic side chain can be enhanced by additional H-bonds in a distance dependent manner: A case study with thrombin inhibitors

  摘要：

  One of the underappreciated non-covalent binding factors, which can significantly affect ligand-protein binding affinity, is the cooperativity between ligand functional groups. Using four different series of thrombin inhibitors, we reveal a strong positive cooperativity between an H-bond accepting carbonyl functionality and the adjacent P3 hydrophobic side chain. Adding an H-bond donating amine adjacent to the P3 hydrophobic side chain further increases this positive cooperativity thereby improving the Ki by as much as 546-fold. In contrast, adding an amidine multiple H-bond/salt bridge group in the distal S1 pocket does not affect this cooperativity. An analysis of the crystallographic B-factors of the ligand groups inside the binding site indicates that the strong cooperativity is mainly due to a significant mutual reduction in the residual mobility of the hydrophobic side chain and the H-bonding functionalities that is absent when the separation distance is large. This type of cooperativity is important to encode in binding affinity prediction software, and to consider in SAR studies. (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.059
• 作为产物：
  描述：

  N-BOC-D-氨基丁酸 、 二甲羟胺盐酸盐 在 N,N'-羰基二咪唑 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 20.5h， 生成 (R)-tert-butyl (1-(methoxy(methyl)amino)-1-oxobutan-2-yl)carbamate
  参考文献：
  名称：

  由N-Boc氨基酸制备α-羟基-β-Fmoc氨基酸

  摘要：

  描述了将N -Boc氨基酸转化为其同源的α-羟基-β-Fmoc氨基酸的一般方法。该方案涉及通过还原相应的Weinreb酰胺，氢氰化和腈基水解来制备氨基醛，然后将氨基酸作为Fmoc衍生物重新保护。 N -Boc氨基酸-还原-氢氰化-N -Fmoc氨基酸

  DOI：

  10.1055/s-0031-1289586

文献信息

• Preparation of α-Hydroxy-β-Fmoc Amino Acids from N-Boc Amino Acids
  作者：Christopher Teleha、Erik Johnson、M. Hubieki、Andrew Combs

  DOI：10.1055/s-0031-1289586

  日期：2011.12

  A general method for the conversion of N-Boc amino acids­ into their homologated α-hydroxy-β-Fmoc amino acids is described. The protocol involved preparation of the amino aldehyde by reduction of the corresponding Weinreb amides, hydrocyanation, and hydrolysis of the nitrile group, followed by reprotection of the amino acid as the Fmoc derivative. N-Boc amino acid - reduction - hydrocyanation - N-Fmoc

  描述了将N -Boc氨基酸转化为其同源的α-羟基-β-Fmoc氨基酸的一般方法。该方案涉及通过还原相应的Weinreb酰胺，氢氰化和腈基水解来制备氨基醛，然后将氨基酸作为Fmoc衍生物重新保护。 N -Boc氨基酸-还原-氢氰化-N -Fmoc氨基酸
• Novel compounds and compositions as cathepsin inhibitors
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US20040142999A1

  公开（公告）日：2004-07-22

  The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.

  本发明涉及一种新型选择性卡硫化酶S抑制剂，其药学上可接受的盐和N-氧化物，其作为治疗剂的用途以及其制备方法。
• [EN] PREPARATION OF SUBSTITUTED 1,2-DIAMINOHETEROCYCLIC COMPOUND DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS<br/>[FR] PRÉPARATION DE DÉRIVÉS DE COMPOSÉS 1,2-DIAMINOHÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION EN TANT QU'AGENTS PHARMACEUTIQUES
  申请人：AVELOS THERAPEUTICS INC

  公开号：WO2022260441A1

  公开（公告）日：2022-12-15

  This invention relates to compounds which are microtubule associated serine/threonine-like kinase (MASTL) inhibitors and the use of the compounds in the treatment of diseases and medical conditions mediated by MASTL, for example in the treatment of cancer and other target related diseases.

  本发明涉及一种微管相关丝氨酸/苏氨酸样激酶（MASTL）抑制剂化合物及其在治疗由MASTL介导的疾病和医学状况中的应用，例如在治疗癌症和其他相关疾病中的应用。
• NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
  申请人：FUJIFILM Corporation

  公开号：EP2589592B1

  公开（公告）日：2018-08-22
• CHEMICAL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS AS CATHEPSIN S INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1397340A2

  公开（公告）日：2004-03-17